Stool Biomarker Detection for Neoplasm Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting premalignant and malignant neoplasms, such as colorectal and pancreatic cancer, are invasive and lack sensitivity and specificity, particularly in early stages, necessitating the development of non-invasive and accurate diagnostic techniques.
Innovation Solution
The use of nucleic acid and polypeptide markers in stool samples to detect cancer, including ratios of elastase 3A to pancreatic alpha-amylase, carboxypeptidase B to carboxypeptidase A2, and DNA fragments of specific lengths, along with digital melt curve analysis and quantitative PCR, to identify mutations in genes like K-ras and APC, enabling early detection and localization of neoplasms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If invasive diagnostic techniques such as endoscopy are used to detect neoplasms, then detection reliability is improved, but patient comfort and ease of operation deteriorate
Solution Approach 1:
The patent uses stool samples as an intermediary medium to detect neoplasms indirectly. Instead of directly examining tissues through invasive procedures, the method analyzes DNA, proteins, and other biomarkers present in stool, which contains shed cells from the gastrointestinal tract. This intermediary approach maintains high detection reliability while eliminating patient discomfort associated with invasive procedures
Solution Approach 2:
The patent replaces mechanical invasive procedures (endoscopy, biopsy) with molecular analysis methods. By substituting physical intervention with biochemical detection of neoplasm-specific markers in stool samples, the system achieves comparable diagnostic accuracy without mechanical intrusion into the patient's body
2Device complexity
If conventional diagnostic methods are used to detect early-stage neoplasms, then simplicity of the method is maintained, but detection precision deteriorates
Solution Approach 1:
The patent segments the detection process into multiple independent analytical components: DNA mutation analysis (K-ras, p53, APC), protein marker detection (carboxypeptidase B/A2 ratio, elastase 3A/alpha-amylase ratio), and methylation status assessment. Each segment targets specific neoplasm characteristics, and their combination achieves high detection precision while maintaining procedural simplicity through standardized testing protocols
Solution Approach 2:
The patent employs a composite diagnostic approach by combining multiple types of biomarkers (nucleic acids, proteins, metabolic products) from the same stool sample. This multi-marker panel strategy enhances detection precision for early-stage neoplasms while maintaining methodological simplicity through integrated analysis of all markers from a single non-invasive sample
3Ease of operation
If non-invasive stool analysis is used to detect neoplasms, then patient comfort is improved, but detection sensitivity deteriorates
Solution Approach 1:
The patent performs preliminary enrichment and concentration of neoplasm-specific markers from stool samples before final analysis. DNA extraction protocols concentrate mutated sequences, and protein assays pre-concentrate enzyme markers, ensuring that even trace amounts of neoplasm-derived material in stool samples achieve detection sensitivity comparable to invasive methods
Solution Approach 2:
The patent employs highly sensitive detection parameters and thresholds specifically calibrated for stool-based analysis. By optimizing detection limits, signal-to-noise ratios, and cutoff values for each marker type, the system achieves high detection sensitivity despite the diluted and complex matrix of stool samples, maintaining reliability while preserving non-invasive benefits
Data Source
AI summary
This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.